对HBV、HCV及非病毒相关HCC的多组学解析揭示不同的增殖、干扰素和代谢特征

Background: Hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, develops through multiple pathways; however, the extent to which HBV, HCV, and non-viral etiologies shape tumor biology and influence treatment responses remain incompletely understood. The availability of viral detection methods from sequencing data and multiomics workflows give us a new opportunities to study how etiology influences the molecular landscape of HCC. Here, we analyze TCGA's LIHC samples categorized into HBV-, HCV-, and non-viral tumors to compare genomic, transcriptomic and methylation profile of these HCC tumors to identify biological pathways specific to each group. Methods: Whole-exome, RNA-seq, and clinical data from TCGA-LIHC (n=325) were analyzed. Viral status was assigned using Exogene (≥5 HBV/HCV reads; mixed infections excluded; non-viral = 0 reads). Mutation and clinical comparisons were performed using cBioPortal. RNA-seq data were processed with edgeR for 3-way differential expression (median count ≥25; |log₂FC|>2; FDR<0.05). Pathway enrichment used ShinyGO. Findings were validated using the GSE62232 microarray cohort analyzed with limma. Results: Demographic patterns reflected known risk profiles: HBV patients presented younger (mean 53.9 years) and were predominantly male (78.8%) and Asian (92.9%), while HCV and non-viral groups were older and primarily White. Non-viral HCC showed the highest proportion of females (42.7%) and nearly half lacked significant fibrosis, consistent with metabolic disease. In contrast, HCV had the highest cirrhosis burden (47.2%), and HBV tumors showed the greatest proportion of poorly differentiated histology (52.2%).The comparison of the expressed genes between the 3 tumor subtypes revealed distinct etiology-associated pathways. Metabolic and mitochondrial including fatty acid beta-oxidation differential expressed in Non-viral HCC. Activation of antiviral and interferon signaling, including type I IFN response and OAS-mediated defense pathways are observed in HCV-HCC. Finally, Cell-cycle and proliferation pathways are differentially expressed in HBV-positive, a finding consistent with effects of viral integration. Clustering analysis separated HBV and non-viral tumors into distinct groups. These signatures were reproduced in a validation cohort. Conclusion: Our analyses highlight that HBV-, HCV-, and non-viral HCC harbor distinct transcriptional and signaling pathways. These etiology-specific signatures provide a framework for developing more precise biomarkers and for tailoring therapeutic strategies to the molecular biology of each etiology. Acknowledgement: We acknowledge the late Dr. Sean Cleary, MD, for his invaluable contributions to this project. Disclosure: AI has been used to trim sentences in order to fit in the word limit.